Pilot Study Testing the Effects of BTK Inhibitor Ibrutinib on Levels and Function of Myeloid Derived Suppressor Cells and Other Immune Subsets in Patients With Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 29 Aug 2018
At a glance
- Drugs Ibrutinib (Primary) ; Nivolumab (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 20 Aug 2018 Status changed from not yet recruiting to recruiting.
- 08 Jun 2018 Planned initiation date changed from 1 Jun 2018 to 1 Aug 2018.
- 18 May 2018 New trial record